EC closes antitrust case against AstraZeneca and Nycomed
This article was originally published in Scrip
Executive Summary
The European Commission has ended its antitrust investigation into AstraZeneca and Nycomed, confirming that it could not find any evidence of wrongdoing. The commission was investigating whether the companies had taken actions to delay the market entry of generic medicines, thereby harming healthcare providers and consumers.